Antimicrobial Resistance Surveillance in Retail Food Specimens
The National Antimicrobial Resistance Monitoring System (NARMS) is a U.S. public health surveillance system that tracks antibiotic resistance in enteric bacteria from humans, retail meats, and food animals. When antimicrobial drugs are used in food-producing animals, they can enrich for populations of resistant strains that reach humans via the food supply. The chief goal of the NARMS retail food surveillance program is to improve the detection of and surveillance for antimicrobial resistance among enteric bacteria in raw retail food commodities, particularly fresh retail meat. The NARMS program is looking to collaborate with institutions or organizations to enhance and strengthen antibiotic resistance surveillance in retail food specimens. Partnering with the NARMS retail food surveillance program will enable the collection of critical data for FDA policy and regulatory actions including but not limited to pre-approval safety evaluation of new animal antibiotics, determining parameters for the antimicrobial use in veterinary medicine, and the ability to provide information to promote interventions to reduce resistance among foodborne bacteria. This collaboration will address NARMS programmatic needs to implement effective surveillance and response for antibiotic resistance as recommended in the National Strategy for Combating Antibiotic-Resistant Bacteria (CARB).
General information about this opportunity
Last Known Status
Food and Drug Administration, Department of Health and Human Services
Type(s) of Assistance Offered
B - Project Grants
Section 1702(a) [42 U.S.C. 300u-1(a)] and Section 1703(a) and (c) [42 U.S.C. 300u-2(a) and (c)] of the Public Health Service Act, as amended
Who is eligible to apply/benefit from this assistance?
Applicants should review the individual funding opportunity announcement issued under this CFDA program to see which applicant organizations are eligible to apply.
Improving antimicrobial resistance surveillance, food safety, and antimicrobial drug approvals for animals and humans.
A nonprofit private entity must provide evidence of its nonprofit status. Applicants should review the individual funding opportunity announcement issued under this CFDA program for any required proof of certification which must be submitted prior to or simultaneous with submission of an application.
What is the process for applying and being award this assistance?
Preapplication coordination is not applicable.
2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. To apply, access the announcement through www.grants.gov. Enter the CFDA# and follow the website instructions. Applications submitted after the deadlines will not be accepted for review. The submission deadline will not be extended. Applications which do not conform to the requirements of the grant announcement will not be accepted for review. Applications may only be submitted electronically via www.grants.gov. Any applications submitted via any other means of electronic communication, including facsimile or electronic mail, will not be accepted for review. Applicants should review the individual funding opportunity announcement issued under this CFDA program for specific application procedures.
Applications will be screened upon receipt. Those that are judged to be ineligible will not be reviewed. Accepted applications will be subject to objective review for technical merit. Applications will be evaluated by an objective review committee composed of experts. Final funding decisions will be determined by the NVPO Office Director; taken into consideration are the recommendations of the review committee; program needs, stated preferences; geographic location. All applicants are notified in writing of actions taken on their applications. A Notice of Award is issued for those applications that are approved and funded. Applicants should review the individual funding opportunity announcement issued under this CFDA program to see the specific award procedures that apply.
Contact the headquarters or regional location, as appropriate for application deadlines
Approval/Disapproval Decision Time
From 60 to 90 days.
Renewals are permitted as indicated in the published funding opportunity announcement issued under this CFDA program. Renewal awards may be approved pending availability of funding and evidence of satisfactory progress and compliance.
How are proposals selected?
Applicants should review the individual Funding Opportunity Announcement issued under this CFDA program to see the specific evaluation criteria that applies.
How may assistance be used?
The assistance can be applied to supplies, equipment, personnel, job training, and/or travel needed to conduct retail food surveillance activities as defined in the cooperative agreement and referenced in the NARMS retail food surveillance protocol. Assistance can be applied to improving the way antibiotic resistance surveillance samples are collected and processed, improve microbiological testing standards, improve quality assurance practices, improve collaboration and coordination of surveillance activities with the FDA, improve the exchange of relevant and complete surveillance data with the FDA, improve the use of data to inform program and policy development, improve data for education on current and emerging hazards, improve awareness of antimicrobial resistance among the public, improve the identification of foodborne illness outbreaks and coordinate outbreak investigations with the FDA, improve the way surveillance data are collected and analyzed, and for conducting ad hoc pilot studies as needed for consensus definitions.
What are the requirements after being awarded this opportunity?
Performance monitoring is required as stated in the Funding Opportunity Announcement and the Terms and Conditions of Award. A final performance report is due 90 days following the end of the project period.
Applicants should review the individual Funding Opportunity Announcement (FOA) issued under this CFDA program to see the specific requirement that applies.
HHS and the Comptroller General of the United States or any of their authorized representatives shall have the right of access to any books, documents, papers, or other records of a grantee, sub-grantee, contractor, or subcontractor, which are pertinent to the HHS grant, in order to make audits, examinations, excerpts and transcripts. In accordance with 45 CFR, Part 74.53 and 45 CFR, Part 92, grantees are required to maintain grant accounting records 3 years after the end of a project period. If any litigation, claim, negotiation, audit or other action involving the records has been started before the expiration of the 3-year period, the records shall be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later.
Other Assistance Considerations
Formula and Matching Requirements
Statutory formula is not applicable to this assistance listing.
Matching requirements are not applicable to this assistance listing.
MOE requirements are not applicable to this assistance listing.
Length and Time Phasing of Assistance
The length of support will depend on the nature of the projects, program relevance and the availability of funds. Awards are usually made for a 12-month period with recommendation of up to 4 years of additional support. Applicants should review the individual funding opportunity announcement issued under this CFDA program to see the specific available length and time that apply. The Notice of Award (NoA) is the legal document issued to notify grantees that an award has been made and that funds may be requested from the designated HHS payment system or office. A NoA is issued for the initial budget period, if subsequent budget periods are also approved, the NoA will include a reference to those budgetary commitments. Funding for subsequent budget periods are generally provided in annual increments following the annual assessment of the project’s progress. This funding is also contingent on the availability of funds. Funds are made available through the DHHS Payment Management System (PMS). Cooperative Agreements may not exceed 5 years (subject to the availability of funds). Necessary instructions for the appropriate type of payment will be issued at the time an award is made.
Who do I contact about this opportunity?
Regional or Local Office
8401 Muirkirk Rd
Laurel, MD 20708 US
(Cooperative Agreements) FY 18$2,500,000.00; FY 19 est $2,348,277.00; FY 20 est $1,981,627.00; FY 16$2,310,556.00; FY 17 est $2,500,000.00; -
Range and Average of Financial Assistance
Estimated $2,500,000 available for anticipated 30 awards.
Regulations, Guidelines and Literature
Applicants should review the individual Funding Opportunity Announcement issued under this CFDA program to see the specific regulations, guidelines, and/or literature that applies. HHS Grants Policy Statement is available online: http://www.hhs.gov/asfr/ogapa/aboutog/hhsgps107.pdf.
Examples of Funded Projects